ClinicalTrials.gg
CompletedNCT00353262Updated Mar 4, 2016Results posted

A Study of Xeloda (Capecitabine) in Combination With Oxaliplatin in Patients With Metastatic Colorectal Cancer.

A Phase 1 interventional study of Avastin and Oxaliplatin in Colorectal Cancer, sponsored by Hoffmann-La Roche. Completed at 3 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-03-04.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 206 studies testing oxaliplatin in Colorectal Neoplasms — 21 open to participants now, 25 under way, 6 of them phase 3. Oxaliplatin · Colorectal Neoplasms.

Enrollment
114th of 183
36 · median 50
Started
2005
with 14 others
Phase 1
29 of 206
4 open now
Registered
77th of 206
by date
Lead sponsor
11 of 206
Hoffmann-La Roche

Among the 206 studies testing oxaliplatin in Colorectal Neoplasms, this one is the 114th largest by enrollment of the 183 interventional ones that give a count, is one of 15 that started in 2005, is one of 29 in phase 1, and was the 77th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

21 of the 206 studies testing oxaliplatin in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About oxaliplatin

Oxaliplatin: first FDA approval 2002 (ELOXATIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies testing oxaliplatin in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This single arm study will investigate possible pharmacokinetic interactions between Xeloda and oxaliplatin, and assess whether the pharmacokinetics of Xeloda and/or oxaliplatin is influenced by the addition of Avastin. All subjects will provide samples for pharmacokinetic analysis during the first 3 cycles of treatment. In cycles 1 and 2 patients will receive a treatment regimen containing Xeloda (1000mg/m2 bid) and oxaliplatin (130mg/m2 iv) and in cycle 3 Avastin (7.5mg/kg iv) will be added to the regimen. The anticipated time on study treatment is 3-12 months, and the target sample size is \<100 individuals.

03

Conditions studied

  • Colorectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients, >=18 years of age;
  • adenocarcinoma of colon or rectum, with or locally advanced disease.

Exclusion criteria

Exclusion Criteria:

  • previous systemic treatment for advanced or disease;
  • previous treatment with oxaliplatin or Avastin.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    1

    Drug: Avastin · Drug: Oxaliplatin · Drug: capecitabine [Xeloda]

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under The Plasma Concentration-Time Curve From Zero To Infinity (AUC0-Inf) of 5'-Deoxy-5-fluorouridine 5'-(DFUR)

    AUC0-infinity represents the area under the concentration-time curve of the analyte (5'-DFUR) in plasma over the time interval from 0 extrapolated to infinity. The analyte 5'-DFUR, the direct precursor of 5-fluorouracil (5-FU), is considered to be the most important metabolite of capecitabine in plasma. The unit of measure was nanograms per millilitre per hour (ng/mL \* hr).

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, and 12 hours post the dose.

  2. AUC0-inf for Free Platinum

    AUC0-infinity represents the area under the concentration-time curve of the analyte (free platinum) in plasma over the time interval from 0 extrapolated to infinity. AUC0-inf for free platinum was calculated for each participant from the concentration-data obtained on Days 2 to 5 of Cycle 1, and Days 1 to 4 for Cycle 2 and 3. Free platinum is not bound to plasma proteins and is considered to be the most clinically significant measure of pharmacological and toxicological activity.

    Time frame: Predose , 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 and 72 hours from the beginning of the 2 hour oxaliplatin infusion on Days 2 to 5 of Cycle 1, and Days 1 to 4 for Cycle 2 and 3.

Secondary outcomes

  1. AUC (0-infinity) of Capecitabine and Its Metabolites (5'-DFCR, 5-FU, and FBAL)

    AUC0-infinity represents the area under the concentration-time curve of the analytes (5'-DFCR, 5-FU, and FBAL) in plasma over the time interval from 0 extrapolated to infinity. After oral administration, capecitabine is first metabolized in the liver to 5'-deoxy-5-fluorocytidine (5'-DFCR), which is then converted to 5'-DFUR, and then catalytically activated to 5-FU.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, and 12 hours post the dose

  2. AUC0-last of Capecitabine and Its Metabolites (5'-DFUR, 5'-DFCR, 5 FU, and FBAL)

    Area under the plasma concentration-time curve from time zero to the time of the last measurable plasma concentration time point of capecitabine and its metabolites (5'-DFUR, 5'-DFCR, 5 FU, and FBAL).

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, and 12 hours post the dose

  3. Maximum Plasma Concentration (Cmax) of Capecitabine and Its Metabolites (5'-DFUR, 5'-DFCR, 5 FU, and FBAL)

    Cmax is defined as maximum observed analyte concentration of capecitabine and its metabolites (5'-DFUR, 5'-DFCR, 5 FU, and FBAL)

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, and 12 hours post the dose

  4. Elimination Half-life Period (t1/2 Beta) of Capecitabine and Its Metabolites (5'-DFUR , 5'-DFCR, 5 FU, and FBAL)

    t1/2 Beta is the time measured for the plasma concentration to decrease by 1 half to its original concentration of capecitabine and its metabolites (5'-DFUR , 5'-DFCR, 5 FU, and FBAL)

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, and 12 hours post the dose

  5. AUC0-infinity for Total Platinum

    AUC0-infinity represents the area under the concentration-time curve of the analyte (total platinum) in plasma over the time interval from 0 extrapolated to infinity.

    Time frame: Pre-dose, and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 and 72 hours from the beginning of the two hour oxaliplatin infusion on Days 2 to 5 of Cycle 1, and Days 1 to 4 for Cycle 2 and 3

  6. AUC0-last of Total And Free Platinum

    Area under the plasma concentration-time curve from time zero to the time of the last measurable plasma concentration time point of Total And Free Platinum.

    Time frame: pre-dose, and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 and 72 hours from the beginning of the two hour oxaliplatin infusion on Days 2 to 5 of Cycle 1, and Days 1 to 4 for Cycle 2 and 3.

  7. Cmax of Total And Free Platinum

    Cmax is defined as maximum observed analyte concentration of Total And Free Platinum.

    Time frame: Pre-dose, and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 and 72 hours from the beginning of the two hour oxaliplatin infusion on Days 2 to 5 of Cycle 1, and Days 1 to 4 for Cycle 2 and 3.

  8. T1/2 Beta of Total And Free Platinum

    T1/2 beta is the time measured for the plasma concentration to decrease by 1 half to its original concentration of total and free platinum.

    Time frame: Pre-dose, and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 and 72 hours from the beginning of the two hour oxaliplatin infusion on Days 2 to 5 of Cycle 1, and Days 1 to 4 for Cycle 2 and 3

  9. Volume of Distribution at Steady State (VSS) of Total And Free Platinum

    VSS is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state.

    Time frame: Pre-dose, and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 and 72 hours

  10. Clearance of Total And Free Platinum

    CL is a calculation of the rate at which a drug is removed from the body via renal, hepatic and other clearance pathways, expressed as volume (milliliters) per unit of time (hour).

    Time frame: Pre-dose, and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 and 72 hours from the beginning of the two hour oxaliplatin infusion on Days 2 to 5 of Cycle 1, and Days 1 to 4 for Cycle 2 and 3

  11. Number Of Participants With Adverse Events (AEs)

    An adverse event is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product. This includes any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Pre-existing conditions which worsened during the study were also to be reported as AEs.

    Time frame: Approximately 3 Years (up to 28 days after the last intake of study medication)

  12. Marked Laboratory Abnormalities

    Number of participants with marked laboratory abnormalities (hematology, coagulation, liver function, renal function, protein, electrolytes, miscellaneous).

    Time frame: Up to 28 days after last chemotherapy administration

07

Results

Posted Jan 8, 2016

Participant flow

A total of 36 participants were enrolled in this study at three sites in Canada between 8 August 2005 and 24 April 2008.

Participant flow — Overall Study
MilestoneCapecitabine+ Oxaliplatin+ Bevacizumab
Started36
Completed7
Not completed29
Withdrew: Adverse event8
Withdrew: Withdrawal by subject2
Withdrew: Insufficient therapeutic response13
Withdrew: Progression1
Withdrew: Surgery4
Withdrew: Break from chemotherapy1

Outcome measures

PrimaryArea Under The Plasma Concentration-Time Curve From Zero To Infinity (AUC0-Inf) of 5'-Deoxy-5-fluorouridine 5'-(DFUR)

AUC0-infinity represents the area under the concentration-time curve of the analyte (5'-DFUR) in plasma over the time interval from 0 extrapolated to infinity. The analyte 5'-DFUR, the direct precursor of 5-fluorouracil (5-FU), is considered to be the most important metabolite of capecitabine in plasma. The unit of measure was nanograms per millilitre per hour (ng/mL \* hr).

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, and 12 hours post the dose.
Reported as:
Geometric mean · ng/mL*hr
Area Under The Plasma Concentration-Time Curve From Zero To Infinity (AUC0-Inf) of 5'-Deoxy-5-fluorouridine 5'-(DFUR)
ng/mL*hrCapecitabine+ Oxaliplatin+ Bevacizumab
Cycle 1, Day 113605 ± 33
Cycle 2, Day 112177 ± 27
Cycle 3, Day 111817 ± 38
Statistical analysis
  • Capecitabine+ Oxaliplatin+ Bevacizumab · Geometric mean ratio: 0.90 · 90% CI 0.79 to 1.02
  • Capecitabine+ Oxaliplatin+ Bevacizumab · Geometric mean ratio: 0.87 · 90% CI 0.76 to 0.99
  • Capecitabine+ Oxaliplatin+ Bevacizumab · Geometric mean ratio: 0.97 · 90% CI 0.85 to 1.10
PrimaryAUC0-inf for Free Platinum

AUC0-infinity represents the area under the concentration-time curve of the analyte (free platinum) in plasma over the time interval from 0 extrapolated to infinity. AUC0-inf for free platinum was calculated for each participant from the concentration-data obtained on Days 2 to 5 of Cycle 1, and Days 1 to 4 for Cycle 2 and 3. Free platinum is not bound to plasma proteins and is considered to be the most clinically significant measure of pharmacological and toxicological activity.

Time frame:
Predose , 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 and 72 hours from the beginning of the 2 hour oxaliplatin infusion on Days 2 to 5 of Cycle 1, and Days 1 to 4 for Cycle 2 and 3.
Reported as:
Geometric mean · ng/mL * hr
AUC0-inf for Free Platinum
ng/mL * hrCapecitabine+ Oxaliplatin+ Bevacizumab
Cycle 1, Day 210069 ± 23
Cycle 2 , Day 110537 ± 24
Cycle 3, Day 1.10225 ± 23
Statistical analysis
  • Capecitabine+ Oxaliplatin+ Bevacizumab · Geometric mean ratio: 1.05 · 90% CI 1.01 to 1.08
  • Capecitabine+ Oxaliplatin+ Bevacizumab · Geometric mean ratio: 1.02 · 90% CI 0.98 to 1.05
  • Capecitabine+ Oxaliplatin+ Bevacizumab · Geometric mean ratio: 0.97 · 90% CI 0.94 to 1.00
SecondaryAUC (0-infinity) of Capecitabine and Its Metabolites (5'-DFCR, 5-FU, and FBAL)

AUC0-infinity represents the area under the concentration-time curve of the analytes (5'-DFCR, 5-FU, and FBAL) in plasma over the time interval from 0 extrapolated to infinity. After oral administration, capecitabine is first metabolized in the liver to 5'-deoxy-5-fluorocytidine (5'-DFCR), which is then converted to 5'-DFUR, and then catalytically activated to 5-FU.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, and 12 hours post the dose
Reported as:
Geometric mean · ng/mL*hr
AUC (0-infinity) of Capecitabine and Its Metabolites (5'-DFCR, 5-FU, and FBAL)
ng/mL*hrCapecitabine+ Oxaliplatin+ Bevacizumab
Capcetabine , Cycle 1, Day 15217 ± 57
Capcetabine , Cycle 2, Day 15299 ± 54
Capcetabine , Cycle 3, Day 16130 ± 68
5'-DFCR , Cycle 1, Day 17630 ± 76
5'-DFCR , Cycle 2, Day 16409 ± 47
5'-DFCR, Cylce 3, Day 17989 ± 52
5-FU , Cycle 1, Day 1437 ± 92
5-FU , Cycle 2, Day 1355 ± 50
5-FU , Cycle 3, Day 1343 ± 86
FBAL , Cycle 1, Day 117904 ± 27
FBAL , Cycle 2, Day 117413 ± 26
FBAL , Cycle 3, Day 117356 ± 34
Statistical analysis
  • Capecitabine+ Oxaliplatin+ Bevacizumab · Geometric mean ratio: 1.02 · 90% CI 0.83 to 1.24
  • Capecitabine+ Oxaliplatin+ Bevacizumab · Geometric mean ratio: 1.16 · 90% CI 0.94 to 1.42
  • Capecitabine+ Oxaliplatin+ Bevacizumab · Geometric mean ratio: 1.17 · 90% CI 0.96 to 1.44
  • Capecitabine+ Oxaliplatin+ Bevacizumab · Geometric mean ratio: 0.86 · 90% CI 0.69 to 1.08
  • Capecitabine+ Oxaliplatin+ Bevacizumab · Geometric mean ratio: 1.08 · 90% CI 0.86 to 1.34
  • Capecitabine+ Oxaliplatin+ Bevacizumab · Geometric mean ratio: 1.25 · 90% CI 1.00 to 1.55
  • Capecitabine+ Oxaliplatin+ Bevacizumab · Geometric mean ratio: 0.81 · 90% CI 0.66 to 1.01
  • Capecitabine+ Oxaliplatin+ Bevacizumab · Geometric mean ratio: 0.79 · 90% CI 0.64 to 0.97
  • Capecitabine+ Oxaliplatin+ Bevacizumab · Geometric mean ratio: 0.97 · 90% CI 0.78 to 1.19
  • Capecitabine+ Oxaliplatin+ Bevacizumab · Geometric mean ratio: 0.97 · 90% CI 0.91 to 1.04
  • Capecitabine+ Oxaliplatin+ Bevacizumab · Geometric mean ratio: 0.97 · 90% CI 0.90 to 1.04
  • Capecitabine+ Oxaliplatin+ Bevacizumab · Geometric mean ratio: 1.00 · 90% CI 0.93 to 1.07
SecondaryAUC0-last of Capecitabine and Its Metabolites (5'-DFUR, 5'-DFCR, 5 FU, and FBAL)

Area under the plasma concentration-time curve from time zero to the time of the last measurable plasma concentration time point of capecitabine and its metabolites (5'-DFUR, 5'-DFCR, 5 FU, and FBAL).

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, and 12 hours post the dose
Reported as:
Geometric mean · ng/mL*hr
AUC0-last of Capecitabine and Its Metabolites (5'-DFUR, 5'-DFCR, 5 FU, and FBAL)
ng/mL*hrCapecitabine+ Oxaliplatin+ Bevacizumab
5' DFUR , Cycle 1, Day 113503 ± 33
5' DFUR, Cycle 2 , Day 112057 ± 28
5' DFUR, Cycle 3, Day 111618 ± 38
Capecitabine, Cycle 1, Day 15201 ± 57
Capecitabine, Cycle 2, Day 15273 ± 54
Capecitabine, Cycle 3, Day 16093 ± 68
5'-DFCR, Cycle 1, Day 16150 ± 80
5'-DFCR, Cycle 2 , Day 16378 ± 47
5'-DFCR, Cycle 3, Day 17909 ± 52
5-FU, Cycle 1, Day 1433 ± 92
5-FU, Cycle 2, Day 1350 ± 51
5-FU, Cycle 3, Day 1336 ± 84
FBAL, Cycle 1, Day 116773 ± 26
FBAL, Cycle 2, Day 115992 ± 26
FBAL, Cycle 3, Day 114947 ± 31
SecondaryMaximum Plasma Concentration (Cmax) of Capecitabine and Its Metabolites (5'-DFUR, 5'-DFCR, 5 FU, and FBAL)

Cmax is defined as maximum observed analyte concentration of capecitabine and its metabolites (5'-DFUR, 5'-DFCR, 5 FU, and FBAL)

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, and 12 hours post the dose
Reported as:
Geometric mean · ng/mL
Maximum Plasma Concentration (Cmax) of Capecitabine and Its Metabolites (5'-DFUR, 5'-DFCR, 5 FU, and FBAL)
ng/mLCapecitabine+ Oxaliplatin+ Bevacizumab
5'-DFUR, Cycle 1, Day 18847 ± 48
5'-DFUR , Cycle 2, Day 16545 ± 48
5'-DFUR , Cycle 3, Day 15693 ± 54
Capecitabine, Cycle 1, Day 14930 ± 72
Capecitabine, Cycle 2, Day 14065 ± 73
Capecitabine, Cycle 3, Day 14167 ± 81
5' DFCR, Cycle 1, Day 13902 ± 78
5' DFCR, Cycle 2, Day 13407 ± 66
5' DFCR , Cycle 3, Day 13747 ± 69
5-FU, Cycle 1 , Day 1292 ± 63
5-FU, Cycle 2, Day 1216 ± 63
5-FU, Cycle 3, Day 1168 ± 83
FBAL, Cycle 1, Day 13970 ± 19
FBAL, Cycle 2, Day 13627 ± 27
FBAL, Cycle 3, Day 13292 ± 34
Statistical analysis
  • Capecitabine+ Oxaliplatin+ Bevacizumab · Geometric mean ratio: 0.74 · 90% CI 0.61 to 0.90
  • Capecitabine+ Oxaliplatin+ Bevacizumab · Geometric mean ratio: 0.64 · 90% CI 0.53 to 0.79
  • Capecitabine+ Oxaliplatin+ Bevacizumab · Geometric mean ratio: 0.87 · 90% CI 0.71 to 1.06
  • Capecitabine+ Oxaliplatin+ Bevacizumab · Geometric mean ratio: 0.82 · 90% CI 0.63 to 1.08
  • Capecitabine+ Oxaliplatin+ Bevacizumab · Geometric mean ratio: 1.03 · 90% CI 0.78 to 1.34
  • Capecitabine+ Oxaliplatin+ Bevacizumab · Geometric mean ratio: 0.85 · 90% CI 0.65 to 1.10
  • Capecitabine+ Oxaliplatin+ Bevacizumab · Geometric mean ratio: 0.87 · 90% CI 0.65 to 1.18
  • Capecitabine+ Oxaliplatin+ Bevacizumab · Geometric mean ratio: 0.96 · 90% CI 0.71 to 1.30
  • Capecitabine+ Oxaliplatin+ Bevacizumab · Geometric mean ratio: 1.10 · 90% CI 0.81 to 1.49
  • Capecitabine+ Oxaliplatin+ Bevacizumab · Geometric mean ratio: 0.74 · 90% CI 0.56 to 0.98
  • Capecitabine+ Oxaliplatin+ Bevacizumab · Geometric mean ratio: 0.58 · 90% CI 0.44 to 0.76
  • Capecitabine+ Oxaliplatin+ Bevacizumab · Geometric mean ratio: 0.78 · 90% CI 0.59 to 1.03
  • Capecitabine+ Oxaliplatin+ Bevacizumab · Geometric mean ratio: 0.91 · 90% CI 0.83 to 1.00
  • Capecitabine+ Oxaliplatin+ Bevacizumab · Geometric mean ratio: 0.83 · 90% CI 0.76 to 0.91
  • Capecitabine+ Oxaliplatin+ Bevacizumab · Geometric mean ratio: 0.91 · 90% CI 0.83 to 1.00
SecondaryElimination Half-life Period (t1/2 Beta) of Capecitabine and Its Metabolites (5'-DFUR , 5'-DFCR, 5 FU, and FBAL)

t1/2 Beta is the time measured for the plasma concentration to decrease by 1 half to its original concentration of capecitabine and its metabolites (5'-DFUR , 5'-DFCR, 5 FU, and FBAL)

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, and 12 hours post the dose
Reported as:
Geometric mean · hour
Elimination Half-life Period (t1/2 Beta) of Capecitabine and Its Metabolites (5'-DFUR , 5'-DFCR, 5 FU, and FBAL)
hourCapecitabine+ Oxaliplatin+ Bevacizumab
5' DFUR; Cycle 1, Day 10.65 ± 19
5' DFUR, Cycle 2 , Day 10.64 ± 49
5' DFUR, Cycle 3, Day 10.75 ± 39
Capecitabine, Cycle 1, Day 10.37 ± 52
Capecitabine, Cycle 2, Day 10.51 ± 55
Capecitabine, Cycle 3, Day 10.56 ± 42
5'-DFCR, Cycle 1, Day 10.71 ± 33
5'-DFCR, Cycle 2 , Day 10.75 ± 32
5'-DFCR, Cycle 3, Day 10.79 ± 24
5-FU, Cycle 1, Day 10.61 ± 20
5-FU, Cycle 2, Day 10.67 ± 61
5-FU, Cycle 3, Day 10.71 ± 31
FBAL, Cycle 1, Day 12.77 ± 19
FBAL, Cycle 2, Day 12.68 ± 26
FBAL, Cycle 3, Day 12.64 ± 33
SecondaryAUC0-infinity for Total Platinum

AUC0-infinity represents the area under the concentration-time curve of the analyte (total platinum) in plasma over the time interval from 0 extrapolated to infinity.

Time frame:
Pre-dose, and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 and 72 hours from the beginning of the two hour oxaliplatin infusion on Days 2 to 5 of Cycle 1, and Days 1 to 4 for Cycle 2 and 3
Reported as:
Geometric mean · ng/mL* hr
AUC0-infinity for Total Platinum
ng/mL* hrCapecitabine+ Oxaliplatin+ Bevacizumab
Cycle 1, Day 2139329 ± 24
Cycle 2, Day 1167610 ± 17
Cycle 3, Day 1186268 ± 21
Statistical analysis
  • Capecitabine+ Oxaliplatin+ Bevacizumab · Geometric mean ratio: 1.20 · 90% CI 1.09 to 1.33
  • Capecitabine+ Oxaliplatin+ Bevacizumab · Geometric mean ratio: 1.34 · 90% CI 1.21 to 1.48
  • Capecitabine+ Oxaliplatin+ Bevacizumab · Geometric mean ratio: 1.11 · 90% CI 1.01 to 1.23
SecondaryAUC0-last of Total And Free Platinum

Area under the plasma concentration-time curve from time zero to the time of the last measurable plasma concentration time point of Total And Free Platinum.

Time frame:
pre-dose, and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 and 72 hours from the beginning of the two hour oxaliplatin infusion on Days 2 to 5 of Cycle 1, and Days 1 to 4 for Cycle 2 and 3.
Reported as:
Geometric mean · ng/mL* hr
AUC0-last of Total And Free Platinum
ng/mL* hrCapecitabine+ Oxaliplatin+ Bevacizumab
Total Platinum: Cycle 1, Day 285406 ± 20
Total Platinum: Cycle 2, Day 197083 ± 12
Total Platinum: Cycle 3, Day 197011 ± 17
Free Platinum: Cycle 1, Day 29399 ± 24
Free Platinum: Cycle 2, Day 19818 ± 25
Free Platinum: Cycle 3, Day 19604 ± 22
SecondaryCmax of Total And Free Platinum

Cmax is defined as maximum observed analyte concentration of Total And Free Platinum.

Time frame:
Pre-dose, and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 and 72 hours from the beginning of the two hour oxaliplatin infusion on Days 2 to 5 of Cycle 1, and Days 1 to 4 for Cycle 2 and 3.
Reported as:
Geometric mean · ng/mL
Cmax of Total And Free Platinum
ng/mLCapecitabine+ Oxaliplatin+ Bevacizumab
Total Platinum: Cycle 1, Day 23652 ± 14
Total Platinum: Cycle 2, Day 13741 ± 19
Total Platinum: Cycle 3, Day 13706 ± 21
Free Platinum: Cycle 1, Day 21818 ± 27
Free Platinum: Cycle 2, Day 11840 ± 36
Free Platinum: Cycle 3, Day 11813 ± 30
Statistical analysis
  • Capecitabine+ Oxaliplatin+ Bevacizumab · Geometric mean ratio: 1.02 · 90% CI 0.96 to 1.09
  • Capecitabine+ Oxaliplatin+ Bevacizumab · Geometric mean ratio: 1.01 · 90% CI 0.95 to 1.08
  • Capecitabine+ Oxaliplatin+ Bevacizumab · Geometric mean ratio: 0.99 · 90% CI 0.93 to 1.05
  • Capecitabine+ Oxaliplatin+ Bevacizumab · Geometric mean ratio: 1.01 · 90% CI 0.94 to 1.09
  • Capecitabine+ Oxaliplatin+ Bevacizumab · Geometric mean ratio: 1.00 · 90% CI 0.92 to 1.08
  • Capecitabine+ Oxaliplatin+ Bevacizumab · Geometric mean ratio: 0.99 · 90% CI 0.91 to 1.07
SecondaryT1/2 Beta of Total And Free Platinum

T1/2 beta is the time measured for the plasma concentration to decrease by 1 half to its original concentration of total and free platinum.

Time frame:
Pre-dose, and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 and 72 hours from the beginning of the two hour oxaliplatin infusion on Days 2 to 5 of Cycle 1, and Days 1 to 4 for Cycle 2 and 3
Reported as:
Geometric mean · hour
T1/2 Beta of Total And Free Platinum
hourCapecitabine+ Oxaliplatin+ Bevacizumab
Total Platinum: Cycle 1, Day 248.70 ± 30
Total Platinum: Cycle 2, Day 155.73 ± 24
Total Platinum: Cycle 3, Day 167.28 ± 26
Free Platinum: Cycle 1, Day 217.64 ± 10
Free Platinum: Cycle 2, Day 118.41 ± 9
Free Platinum: Cycle 3, Day 118.47 ± 10.90
SecondaryVolume of Distribution at Steady State (VSS) of Total And Free Platinum

VSS is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state.

Time frame:
Pre-dose, and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 and 72 hours
Reported as:
Geometric mean · mL
Volume of Distribution at Steady State (VSS) of Total And Free Platinum
mLCapecitabine+ Oxaliplatin+ Bevacizumab
Total Platinum: Cycle 1, Day 2109007 ± 23
Total Platinum: Cycle 2, Day 1105097 ± 21
Total Platinum: Cycle 3, Day 1112141 ± 21
Free Platinum: Cycle 1, Day 2387158 ± 23
Free Platinum: Cycle 2, Day 1389193 ± 29
Free Platinum: Cycle 3, Day 1401040 ± 24
SecondaryClearance of Total And Free Platinum

CL is a calculation of the rate at which a drug is removed from the body via renal, hepatic and other clearance pathways, expressed as volume (milliliters) per unit of time (hour).

Time frame:
Pre-dose, and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 and 72 hours from the beginning of the two hour oxaliplatin infusion on Days 2 to 5 of Cycle 1, and Days 1 to 4 for Cycle 2 and 3
Reported as:
Geometric mean · mL/Hr
Clearance of Total And Free Platinum
mL/HrCapecitabine+ Oxaliplatin+ Bevacizumab
Total Platinum: Cycle 1, Day 21603 ± 78
Total Platinum: Cycle 2, Day 11331 ± 22
Total Platinum: Cycle 3, Day 11198 ± 25
Free Platinum: Cycle 1, Day 222183 ± 23
Free Platinum: Cycle 2, Day 121176 ± 26
Free Platinum: Cycle 3, Day 121823 ± 23
SecondaryNumber Of Participants With Adverse Events (AEs)

An adverse event is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product. This includes any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Pre-existing conditions which worsened during the study were also to be reported as AEs.

Time frame:
Approximately 3 Years (up to 28 days after the last intake of study medication)
Reported as:
Number · Participants
Number Of Participants With Adverse Events (AEs)
ParticipantsCapecitabine+ Oxaliplatin+ Bevacizumab
Any AE36
Any SAE16
SecondaryMarked Laboratory Abnormalities

Number of participants with marked laboratory abnormalities (hematology, coagulation, liver function, renal function, protein, electrolytes, miscellaneous).

Time frame:
Up to 28 days after last chemotherapy administration
Reported as:
Number · Participants
Marked Laboratory Abnormalities
ParticipantsCapecitabine+ Oxaliplatin+ Bevacizumab
Hematocrit - high2
Hematocrit - low5
Hemoglobin - low6
Platelets - high1
Platelets - low9
RBC - low12
WBC - high1
WBC - low7
Neutrophils - high1
Neutrophils - low3
PT (INR) - high2
ASAT (SGOT) - high6
LDH - high2
ALAT (SGPT) - high7
Alk. Phos. - high6
Dir. Bilirubin - high3
Total Bilirubin - high2
Creatinine - high0
Albumin - low4
Potassium - low2
Sodium - low2
Calcium - low1
Glucose Fasting - high4

Adverse events

Collected over Approximately 3 Years (up to 28 days after the last intake of study medication). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Capecitabine+ Oxaliplatin+ Bevacizumab—16/36 (44.4%)36/36 (100%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventCapecitabine+ Oxaliplatin+ Bevacizumab
DehydrationMetabolism and nutrition disorders6/36
DiarrhoeaGastrointestinal disorders4/36
PyrexiaGeneral disorders3/36
Abdominal painGastrointestinal disorders2/36
Gastrointestinal haemorrhageGastrointestinal disorders2/36
NeutropeniaBlood and lymphatic system disorders2/36
EnteritisGastrointestinal disorders1/36
Intestinal obstructionGastrointestinal disorders1/36
VomitingGastrointestinal disorders1/36
PainGeneral disorders1/36
Most frequent other events
Showing 10 of 91
Most frequent other events
EventCapecitabine+ Oxaliplatin+ Bevacizumab
FatigueGeneral disorders32/36
NauseaGastrointestinal disorders30/36
DiarrhoeaGastrointestinal disorders29/36
Peripheral sensory neuropathyNervous system disorders22/36
VomitingGastrointestinal disorders21/36
Palmar-plantarSkin and subcutaneous tissue disorders20/36
AnorexiaMetabolism and nutrition disorders20/36
Abdominal painGastrointestinal disorders14/36
Neuropathy peripheralNervous system disorders14/36
NeutropeniaBlood and lymphatic system disorders11/36

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Capecitabine+ Oxaliplatin+ Bevacizumab
Mean57.3 ± 13.03
Sex: Female, Male
Sex: Female, Male(Participants)Capecitabine+ Oxaliplatin+ Bevacizumab
Female21
Male15
08

Study locations

3 sites
  • Hamilton, Ontario L8V 5C2, Canada
  • Ottawa, Ontario K1H 8L6, Canada
  • Toronto, Ontario M5G 2M9, Canada
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2005, a primary completion of Sep 2006 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2016, 9 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2006
First posted
Jul 18, 2006
Start
Jul 2005
Primary completionActual
Sep 2006
CompletionActual
Apr 2008
Results first posted
Jan 8, 2016
Last update
Mar 4, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00353262
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jul 18, 2006
Start date
Jul 2005
Primary completion
Sep 2006
Completion
Apr 2008
Results posted
Jan 8, 2016
Last update
Mar 4, 2016

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Oxaliplatin

Start the discussion